Breast Cancer Drug Herceptin Linked to Risk of Heart Problems: Study
But most of these effects reverse after women finish treatment, experts say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 10, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Cardiology, Gynecology, Oncology, Pharmacy, News, Source Type: news

Kadmon initiates Phase Ib/IIa trial of KD019 and Trastuzumab to treat HER2+ breast cancer
US-based Kadmon has started a Phase Ib/IIa trial of KD019, an orally bioavailable small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR, in combination with trastuzumab (Herceptin) to treat HER2+ breast cancer metastasized to the brain. (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2014 Category: Pharmaceuticals Source Type: news

ASCO: Herceptin Still a Boon for Small Breast Tumors
CHICAGO (MedPage Today) -- The monoclonal antibody trastuzumab (Herceptin) was beneficial for women with small tumors, according to a new meta-analysis of the randomized trials of the drug. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 3, 2014 Category: Hematology Source Type: news

ALTTO Disappoints Clinicians and Upends ResearchALTTO Disappoints Clinicians and Upends Research
Adding lapatinib to trastuzumab does not improve outcomes in the adjuvant setting, in contrast to what was seen in the neoadjuvant setting. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GlaxoSmithKline plc (LSE: GSK) today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab as adjuvant treatment for HER2 positive early breast cancer (Source: GSK news)
Source: GSK news - June 1, 2014 Category: Pharmaceuticals Source Type: news

ALTTO test of dual HER2 blockade finds single agent remains the gold standard
(Mayo Clinic) In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib did not add benefit to the standard trastuzumab adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2014 Category: Global & Universal Source Type: news

ALTTO Test of Dual HER2 Blockade Finds Single Agent - Trastuzumab - Remains Gold Standard
http://www.youtube.com/watch?v=PAyvFbGlWKY&feature=youtu.be Journalists: Broadcast soundbites with Dr. Perez are available in the downloads. CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 1, 2014 Category: Databases & Libraries Source Type: news

Sure, We'll (Eventually) Beat Cancer. But Can We Afford To?
Matt Herper’s tour de force article in the latest Forbes magazine suggests that companies and researchers are – perhaps – turning the tables on cancer using novel immunotherapies that are producing nearly unheard of outcomes even in late stage disease. The trillion dollar question: Can we afford to win the war on cancer, given current trends in drug development and pricing? What is really remarkable about Herper’s article is how quickly the oncology field is changing.  The search for drugs over the last decade or so has focused on disrupting tumor biology through targeted therapies modeled aft...
Source: Forbes.com Healthcare News - May 17, 2014 Category: Pharmaceuticals Authors: Paul Howard Source Type: news

New ASCO Guidelines Address HER2-Positive Breast CancerNew ASCO Guidelines Address HER2-Positive Breast Cancer
New ASCO guidelines recommend HER2-targeted therapy for most patients with HER2-positive advanced breast cancer, using trastuzumab, pertuzumab, and taxane for first-line treatment. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 8, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New breast cancer drug ‘unaffordable’ for NHS
Charities disappointed at NICE’s draft decision not to recommend KadcylaRelated items from OnMedicaMortality higher if using paroxetine and tamoxifenBreast cancer rate falls with decline in HRT useData don’t support HRT for chronic disease preventionBenefit of Herceptin in more breast cancer casesDrugs regulators “put profits before patients” (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 23, 2014 Category: UK Health Source Type: news

Vials of trastuzumab stolen in Italy and redistributed in other countries under false credentials
Read the full story on MD Consult: Vials of trastuzumab stolen in Italy and redistributed in other countries under false credentials (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - April 21, 2014 Category: Journals (General) Source Type: news

EMA Warns Of Stolen And Tampered Herceptin Vials
The European Medicines Agency has alerted healthcare professionals in the EU after identifying falsified Herceptin (trastuzumab) vials. Herceptin is Roche’s breast cancer drug containing the active drug trastuzumab. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 17, 2014 Category: Pharmaceuticals Source Type: news

EU Warning: Herceptin Vials Have Been Tampered WithEU Warning: Herceptin Vials Have Been Tampered With
The European Medicines Agency is warning about a problem with a small number of batches of Herceptin (trastuzumab) for breast cancer. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Promising drug doubles positive effect in hormone-receptor–positive breast cancer
Breast cancer researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center announced final clinical trial results this week that showed the amount of time patients were on treatment without their cancer worsening (called "progression-free survival") was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.   The results of the phase 2 clinical trial were announced at the American Association for Cancer Research annual meeting in San Diego.   Palbociclib (PD 0332991) is an investigational drug discovered and ...
Source: UCLA Newsroom: Health Sciences - April 11, 2014 Category: Universities & Medical Training Source Type: news

Promising drug doubles positive effect in hormone-receptor–positive breast cancer
Breast cancer researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center announced final clinical trial results this week that showed the amount of time patients were on treatment without their cancer worsening (called "progression-free survival") was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.   The results of the phase 2 clinical trial were announced at the American Association for Cancer Research annual meeting in San Diego.   Palbociclib (PD 0332991) is an investigational drug discovered and ...
Source: UCLA Newsroom: Health Sciences - April 11, 2014 Category: Universities & Medical Training Source Type: news

Aspirin linked to better colon cancer survival
Low-dose aspirin improves survival in some types of colon cancerRelated items from OnMedicaAspirin could also treat cancer, research suggestsAspirin as effective as warfarin for heart patientsAspirin to fight cancer is safe after screeningNICE says far more people should take statinsNICE recommends Herceptin for gastric cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 1, 2014 Category: UK Health Source Type: news

Cash for new cervical cancer drug
Some 500 women in England could benefit as new drug added to approved cancer drugs fundRelated items from OnMedicaNew multi-million pound fund to boost cancer drug developmentInjectable form of Herceptin could simplify breast cancer treatmentNICE rejects use of Avastin for breast cancerNew five-year pricing deal on NHS branded medicines agreed Some expensive cancer drugs could become more widely available (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 6, 2014 Category: UK Health Source Type: news

Oncothyreon and Array begin Phase Ib breast cancer combination therapy study
Oncothyreon and Array BioPharma have started a Phase Ib study of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) for the treatment of patients with metastatic HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 24, 2014 Category: Pharmaceuticals Source Type: news

China Atorvastatin & Trastuzumab Market with 2018 Forecasts in New...
ChinaMarketResearchReports.com adds Latest Reports on Atorvastatin and Trastuzumab industry for China to its store.(PRWeb February 15, 2014)Read the full story at http://www.prweb.com/releases/atorvastatin-trastuzumab/china-market-reports/prweb11585316.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 16, 2014 Category: Pharmaceuticals Source Type: news

Roche Lawsuit Blocks Mylan's Herceptin Biosimilar
Roche is suing Mylan, Biocon and the India regulatory agency over the launch of a breast cancer biosimilar in India. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 11, 2014 Category: Pharmaceuticals Source Type: news

Vitamin C kills cancer cells
Injections of high dose vitamin C could be a cheap treatment for ovarian and other cancersRelated items from OnMedicaNational research funding for cancer rose 60% in a decadeDoubt cast on health benefits of vitamin D supplementsScientists harness immune system to fight cancerBenefit of Herceptin in more breast cancer casesAspirin could also treat cancer, research suggests (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 10, 2014 Category: UK Health Source Type: news

Health groups lash out at HC order baning Biocon, Mylan from selling biosimilar breast cancer drug
Public health groups lashed out at High Court order that stopped Biocon, Mylan from selling biosimilar versions of breast cancer drug Herceptin. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 7, 2014 Category: Pharmaceuticals Source Type: news

Roche sues Biocon, Mylan, DCGI over breast cancer drug
Roche has sued Mylan, Biocon for launching biosimilar version of the original breast cancer drug, Herceptin, and DCGI for allowing the launch. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 6, 2014 Category: Pharmaceuticals Source Type: news

NHS England Adds Three New Therapies To Cancer Drugs Fund List
Roche’s Trastuzumab emtansine, Bayer’s Radium-223 dichloride, and GlaxoSmithKline’s Dabrafenib have been added to the National Health Service’s (NHS) Cancer Drugs Fund list. NHS England released the update this week. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 6, 2014 Category: Pharmaceuticals Source Type: news

Oncothyreon and Array start phase 1b ONT-380 combination trial to treat metastatic HER2+ breast cancer
US-based Oncothyreon and Array BioPharma have started a phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda (capecitabine) and/or Herceptin (trastuzumab) for the treatment of patients with metastatic HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 4, 2014 Category: Pharmaceuticals Source Type: news

Mylan launches breast cancer drug in India
Drug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2014 Category: Pharmaceuticals Source Type: news

Biocon breast cancer drug too expensive, say health activists
Biocon’s launch of the world’s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 20, 2014 Category: Pharmaceuticals Source Type: news

The Cancer Divide: India’s Efforts to Aid Poor Worry Drug Makers
The government threatened to allow production of less costly versions of an effective treatment for a form of breast cancer, a move the pharmaceutical industry says threatens the system for discovering cures.     (Source: NYT Health)
Source: NYT Health - December 30, 2013 Category: Consumer Health News Authors: By GARDINER HARRIS Tags: India Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Roche Holding A G RHHBY Other OTC Novartis AG NVS NYSE Herceptin (Drug) Cancer Breast Cancer Medicine and Health Generic Brands and Products Bayer AG BAYRY Other OTC Source Type: news

With new multimillion-dollar grants, UCLA scientists take stem cell research to patients
Scientists from UCLA are now bringing their groundbreaking stem cell science directly to patients in two exciting new clinical trials scheduled to begin in early 2014, thanks to funding from California's stem cell agency.   The new grants to researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, which total nearly $21 million, were announced Dec. 12 at a meeting of the California Institute of Regenerative Medicine (CIRM) Citizen's Oversight Committee. They are apart of the state agency's Disease Team Therapy Development III initiative.   A team led by UCLA's Dr. Denni...
Source: UCLA Newsroom: Health Sciences - December 16, 2013 Category: Universities & Medical Training Source Type: news

Halaven Plus Herceptin Winning Combo (CME/CE)
SAN ANTONIO (MedPage Today) -- Treatment with the chemotherapy agent eribulin (Halaven) plus trastuzumab (Herceptin) extends progression-free survival among women with metastatic breast cancer, researchers said here. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 16, 2013 Category: Hematology Source Type: news

As Herceptin Goes Off Patent, 'Biosimilars' EmergeAs Herceptin Goes Off Patent, 'Biosimilars' Emerge
Don't call them generics; biosimilars are a different kind of product and are in development in at least 3 countries. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Highly effective treatment option identified for patients with HER2-positive breast cancer
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

In lower-risk breast cancer patients, Herceptin plus Taxol highly effective
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Identifying breast cancer patients most likely to benefit from trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Event-free and overall survival results from NeoALTTO trial
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial were presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Drug cuts breast cancer by half in high-risk women
53% less risk of cancer in post-menopausal women who took drugRelated items from OnMedicaData don’t support HRT for chronic disease preventionBenefit of Herceptin in more breast cancer casesBreast cancer rate falls with decline in HRT useEarly HRT may raise cancer riskPros of Herceptin outweigh cons for breast cancer, finds study (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 13, 2013 Category: UK Health Source Type: news

Study Predicts Moderate Benefit of Trastuzumab in HER2-Negative Breast C...Study Predicts Moderate Benefit of Trastuzumab in HER2-Negative Breast C...
Although trastuzumab (Herceptin) is directed against the HER2 protein, patients with HER2-negative breast cancer might also benefit from adjuvant trastuzumab therapy, new research suggests. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Boston Doctor Part Of Study That Could Change Treatment For Some Breast Cancers
BOSTON (CBS) — A new study may change the way some breast cancers are treated. WBZ NewsRadio 1030′s Diane Stern reports play pause Boston Doctor Part Of Study That Could Change Treatment For Some Breast Cancers Diane Stern Dr. Eric Winer, chief of the division of Women’s Cancers in the Susan F. Smith Center for Women’s Cancers at Dana-Farber,says researchers have discovered women with relatively small, H...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 12, 2013 Category: Consumer Health News Authors: Kckatzman Tags: Breast Cancer Health Healthwatch Local Seen On WBZ-TV Syndicated Local Uncategorized Watch Listen CBS Boston Dana Farber Cancer Institute Diane Stern Dr Eric Winer Research Source Type: news

Breast Cancer Response Before Surgery Matters (CME/CE)
SAN ANTONIO (MedPage Today) -- Complete pathologic responses seen with neoadjuvant trastuzumab (Herceptin) and lapatinib (Tykerb) among breast cancer patients correlated with better survival, according to a clinical trial subanalysis. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2013 Category: Hematology Source Type: news

Herceptin plus taxol highly effective in lower-risk breast cancer patients
(Loyola University Health System) A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

Study identifies highly effective treatment option for patients with HER2-positive breast cancer
(American Association for Cancer Research) Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab
(American Association for Cancer Research) Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

Researchers to present event-free and overall survival results from NeoALTTO trial
(American Association for Cancer Research) Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

Timing of Trastuzumab Administration in Breast CancerTiming of Trastuzumab Administration in Breast Cancer
In the neoadjuvant treatment of HER2-positive breast cancer, administering trastuzumab concurrently with anthracyclines offers no advantage over sequential administration. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biosimilar Trastuzumab (Hertraz) Approved in IndiaBiosimilar Trastuzumab (Hertraz) Approved in India
Three months after the patent on Herceptin expired in India, a biosimilar trastuzumab has been approved there, with a launch planned in early 2014. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 27, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Biocon gets DCGI nod to market biosimilar trastuzumab in India
Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2013 Category: Pharmaceuticals Source Type: news

EU Approves Trastuzumab Emtansine for HER2 Breast Cancer EU Approves Trastuzumab Emtansine for HER2 Breast Cancer
Kadcyla, the novel product that links trastuzumab with a cytotoxic, has been approved in the European Union (EU) for HER2 metastatic breast cancer. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 20, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer
Roche today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. (Source: Roche Media News)
Source: Roche Media News - November 20, 2013 Category: Pharmaceuticals Source Type: news

Combination therapy not necessary to achieve remission in breast cancer patients with HER-2-positive disease
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 14, 2013 Category: Cancer & Oncology Source Type: news

Cardiac Testing in Breast Cancer Treated With TrastuzumabCardiac Testing in Breast Cancer Treated With Trastuzumab
Are women being monitored for cardiac toxicity associated with trastuzumab? Personalized Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news